There is already a drug that fights Alzheimer's

It was at the end of November that the pharmaceutical company Eisai (Japan) and the pharmaceutical company Biogen (United States) revolutionized the industry with a new drug that promises to slow the cognitive decline of patients.

Legembi, the name given to this intravenous drug, was approved in the US on January 7 and promises to help the tens of millions of people suffering from this disease. This medicine is administered once every two weeks.

At the moment, this treatment costs 26,500 dollars per year, that is, more than 2,000 dollars per month. The goal of both pharmaceutical companies is to be able to lower the price and make it accessible to all people.